Serum Institute plans to start vaccine production outside India: Report

The Serum Institute of India, which manufactures the AstraZeneca coronavirus (Covid-19) vaccine, is planning to start vaccine production in other countries as it struggles to meet supply commitments, its chief executive officer told The Times.

“There’s going to be an announcement in the next few days,” Adar Poonawalla was quoted as saying by the newspaper in an interview published on Friday.

Poonawalla said last week that the Serum Institute would be able to raise its monthly output to 100 million doses by July, later than a previous timeline of end-May. Several states in India have run out of vaccines against Covid-19.

He hoped to increase the Serum Institute’s production capacity from 2.5 billion to 3 billion doses a year within six months, the Times reported, adding that he flew to London before Britain banned travellers from India eight days ago.

Coronavirus cases and deaths have surged in India as the world’s second-most populous country has reported more than 300,000 new infections daily for nine consecutive days, hitting another global record of 386,452 on Friday.

The surge has led to a public health crisis and forced the government to seek oxygen, medicines and other essentials from abroad.

The nation’s coronavirus cases may peak between May 3-5, according to scientists advising the government.

Some health experts said India became complacent when new cases were running at about 10,000 a day and the novel coronavirus seemed to be under control. Authorities lifted restrictions, allowing the resumption of large festivals and political rallies.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor